Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Daratumumab: this drug | Approved | Monoclonal antibody | CD38 | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | ||
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | ||
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | ||
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | ||
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | ||
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | ||
| SG301 | Phase 3 | Monoclonal antibody | CD38 | ||
| TJ202 | Phase 3 | Monoclonal antibody | CD38 | ||
| CID-103 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| CM313 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| STI-6129 | Phase 1/2 | Antibody–drug conjugate | CD38 | ||
| SAR442085 | Phase 1 | Biologic (subtype unspecified) | CD38 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome |
…and 58 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Isatuximab · Multiple Myelomavs Mezagitamab · Multiple Myelomavs TJ202 · Multiple Myelomavs CID-103 · Multiple Myelomavs CM313 · Multiple Myelomavs SAR442085 · Multiple Myeloma
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(127 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (13)
October 2026 (4)
Phase 2Light Chain (AL) AmyloidosisActive not recruiting
Est. primary completion 2026-10-14 · NCT06629818 · CT.gov ↗
What to watch
Phase 1/2Autoimmune DisordersRecruiting
Est. primary completion 2026-10-16 · NCT05671757 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-10-20 · NCT06140966 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2026-10-31 · NCT05581875 · CT.gov ↗
What to watch
November 2026 (4)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 3Anti-N-Methyl-D-Aspartate Receptor EncephalitisRecruiting
Est. primary completion 2026-11-08 · NCT06867991 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04922723 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 4Hemophilia A With InhibitorRecruiting
Est. primary completion 2026-12-01 · NCT05888870 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07764861 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06697483 · CT.gov ↗
What to watch
2027 (45)
January 2027 (3)
Phase 2Amyloid, AL Amyloidosis, Refractory AL AmyloidosisActive not recruiting
Est. primary completion 2027-01 · NCT04270175 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-01 · NCT06827860 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (5)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-03 · NCT07362199 · CT.gov ↗
What to watch
Phase 4Microvascular Inflammation - MVI in Kindey Transplant RecipientsActive not recruiting
Est. primary completion 2027-03-01 · NCT07274462 · CT.gov ↗
What to watch
Phase 1Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaRecruiting
Est. primary completion 2027-03-23 · NCT05363111 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-10 · NCT06622005 · CT.gov ↗
What to watch
Phase 4Acquired HemophiliaRecruiting
Est. primary completion 2027-04-30 · NCT05849740 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaNot yet recruiting
Est. primary completion 2027-05 · NCT07721350 · CT.gov ↗
What to watch
Phase 2Plasma Cell Myeloma, Secondary AmyloidosisActive not recruiting
Est. primary completion 2027-05-17 · NCT03346135 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06015724 · CT.gov ↗
What to watch
Phase 2Kidney Failure, Paraproteinemias, GlomerulonephritisRecruiting
Est. primary completion 2027-06 · NCT06889948 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT05572229 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2027-06-29 · NCT07191379 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT05289687 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗
What to watch
Phase 2Plasmablastic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT04497961 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic LymphomaRecruiting
Est. primary completion 2027-09 · NCT04972942 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-09 · NCT06398457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-08 · NCT04635189 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (6)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-11 · NCT07297563 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-11-01 · NCT06142396 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-11-15 · NCT06952478 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT05231629 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1/2Aplastic Anemia, Refractory, RelapseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07287228 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT06107738 · CT.gov ↗
What to watch
Phase 2AL Amyloidosis (AL), t(11;14) PositiveRecruiting
Est. primary completion 2027-12-31 · NCT07335887 · CT.gov ↗
What to watch
Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
2028 (21)
February 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruiting
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02-28 · NCT06948084 · CT.gov ↗
What to watch
March 2028 (5)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2028-03 · NCT07221032 · CT.gov ↗
What to watch
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-03 · NCT07362238 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
May 2028 (2)
July 2028 (2)
August 2028 (3)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
Phase 2Proliferative Glomerulonephritis With Monoclonal IgG DepositsActive not recruiting
Est. primary completion 2028-08 · NCT05654506 · CT.gov ↗
What to watch
Phase 1Adult Patients With Adverse Risk Acute Myeloblastic LeukemiaRecruiting
Est. primary completion 2028-08-06 · NCT05749276 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)Not yet recruiting
Est. primary completion 2028-10-29 · NCT07110662 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-11 · NCT07234019 · CT.gov ↗
What to watch
2029 (17)
January 2029 (5)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 2Primary Plasma Cell LeukemiaRecruiting
Est. primary completion 2029-01-05 · NCT06636552 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
April 2029 (2)
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
July 2029 (2)
Phase 1Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2029-07 · NCT04139304 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-07-24 · NCT07099391 · CT.gov ↗
What to watch
August 2029 (1)
October 2029 (1)
Phase 2T-Lymphocytic Leukemia, AcuteActive not recruiting
Est. primary completion 2029-10 · NCT06253637 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2029-11-30 · NCT05898646 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
Phase 3Smoldering Plasma Cell MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3AL AmyloidosisRecruiting
Est. primary completion 2030-07-29 · NCT06022939 · CT.gov ↗
What to watch
September 2030 (2)
October 2030 (2)
2031 (9)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch
March 2031 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-03-06 · NCT07681596 · CT.gov ↗
What to watch
April 2031 (2)
May 2031 (2)
June 2031 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2Amyloid Light-chain AmyloidosisRecruiting
Est. primary completion 2031-10 · NCT07110844 · CT.gov ↗
What to watch
2032 (4)
September 2032 (2)
2033 (3)
June 2033 (2)
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 2Lymphoma, Primary EffusionRecruiting
Est. primary completion 2034-08-01 · NCT05907759 · CT.gov ↗
What to watch
2035 (2)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (2)
2040 (1)
September 2040 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2040-09 · NCT07095452 · CT.gov ↗
What to watch
2044 (1)
September 2044 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2044-09 · NCT06358638 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.